A phase II study of retifanlimab (INCMGA00012) in patients ...
Retifanlimab, a PD-1 inhibitor, showed clinically meaningful antitumor activity in patients with platinum-refractory squamous carcinoma of the anal canal (SCAC), with an ORR of 13.8% and stable disease in 35.1%, achieving a DCR of 48.9%. Responses were durable, with a median DOR of 9.5 months, and the safety profile was consistent with PD-(L)1 inhibitors.
Reference News
A phase II study of retifanlimab (INCMGA00012) in patients ...
Retifanlimab, a PD-1 inhibitor, showed clinically meaningful antitumor activity in patients with platinum-refractory squamous carcinoma of the anal canal (SCAC), with an ORR of 13.8% and stable disease in 35.1%, achieving a DCR of 48.9%. Responses were durable, with a median DOR of 9.5 months, and the safety profile was consistent with PD-(L)1 inhibitors.